SC
TEVA icon

Sculptor Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Sculptor Capital’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-7,381,900
Closed -$371M – 383
2016
Q2 		$371M Buy
7,381,900
+2,286,100
+45% +$122M 2.13% 6
2016
Q1 		$273M Buy
5,095,800
+136,500
+3% +$8.01M 1.39% 19
2015
Q4 		$326M Buy
+4,959,300
New +$306M 1.78% 13
2014
Q4 		– Sell
-392,500
Closed -$21.1M – 826
2014
Q3 		$21.1M Buy
392,500
+100,000
+34% +$5.3M 0.06% 256
2014
Q2 		$15.3M Sell
292,500
-479,700
-62% -$24.5M 0.05% 324
2014
Q1 		$40.8M Buy
772,200
+387,200
+101% +$17.9M 0.13% 160
2013
Q4 		$15.4M Buy
385,000
+125,000
+48% +$4.92M 0.04% 386
2013
Q3 		$9.82M Hold
260,000
– – 0.03% 451
2013
Q2 		$10.2M Buy
+260,000
New +$10.1M 0.03% 420

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Sculptor Capital's TEVA Position: Q2 2017 in Review

Sculptor Capital sold out of Teva Pharmaceuticals (TEVA) in Q2 2017, closing a stake of 14,016 shares — an estimated $450K sold.

Sculptor Capital first reported a position in TEVA in Q2 2013 and held it in 11 quarters. The position peaked at $431M in Q1 2016. 648 funds tracked by Wall St. Rank hold TEVA as of Q2 2017.

  • Sculptor Capital reported no remaining Teva Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Sculptor Capital sold 14,016 Teva Pharmaceuticals shares in Q2 2017, an estimated $450K.
  • Sculptor Capital first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 11 quarters.
  • Sculptor Capital's Teva Pharmaceuticals position peaked at $431M in Q1 2016.
  • 648 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2017.

Based on Sculptor Capital's 13F filing for Q2 2017, filed 8 Aug 2017.